title: Efficacy of two one-week rabeprazole/levofloxacin-based triple therapies for Helicobacter pylori infection.
abstract: BACKGROUND
  One-week low-dose proton pump inhibitor-based triple therapies have usually proved to be effective treatments for Helicobacter pylori infection.
  
  
  OBJECTIVE
  To investigate the eradication efficacy, safety profile and patient compliance of two triple therapies containing a standard dose of rabeprazole and a new fluoroquinolone, levofloxacin.
  
  
  METHODS
  One hundred patients referred to us for gastroscopy, who were H. pylori-positive, were consecutively recruited in a prospective, open-label study. The enrolled patients were randomised to receive a seven-day course of rabeprazole 20 mg o.d. plus levofloxacin 500 mg o.d. and either amoxycillin 1 g b.d. (RLA group) or tinidazole 500 mg b.d. (RLT group). Their H. pylori status was assessed by means of histology and rapid urease test at entry, and by 13C-urea breath test 8 weeks after the end of treatment.
  
  
  RESULTS
  All 100 enrolled patients completed the study. Forty-six of 50 patients treated with RLA (both PP and ITT analysis: 92%; 95% CI: 81-98%) and 45 of 50 with RLT (both PP and ITT analysis: 90%: 95% CI: 78-97%), became H. pylori-negative. Slight or mild side-effects occurred in 4 (8%) patients of the RLA group and in 5 (10%) of the RLT group.
  
  
  CONCLUSIONS
  This study demonstrates the efficacy of two 1-week rabeprazole-based triple therapies including levofloxacin to eradicate H. pylori. These regimens prove to be safe, well-tolerated, and achieved good eradication rates. Levofloxacin may be an effective alternative to clarithromycin in triple therapy regimens.
authors.affiliation: Department of Internal Medicine, Catholic University of Rome, Italy. gcammarota@libero.it
authors.forename: G
authors.initials: G
authors.lastname: Cammarota
authors.forename: R
authors.initials: R
authors.lastname: Cianci
authors.forename: O
authors.initials: O
authors.lastname: Cannizzaro
authors.forename: L
authors.initials: L
authors.lastname: Cuoco
authors.forename: G
authors.initials: G
authors.lastname: Pirozzi
authors.forename: A
authors.initials: A
authors.lastname: Gasbarrini
authors.forename: A
authors.initials: A
authors.lastname: Armuzzi
authors.forename: M A
authors.initials: MA
authors.lastname: Zocco
authors.forename: L
authors.initials: L
authors.lastname: Santarelli
authors.forename: F
authors.initials: F
authors.lastname: Arancio
authors.forename: G
authors.initials: G
authors.lastname: Gasbarrini
mesh_terms: D053799:2-Pyridinylmethylsulfinylbenzimidazoles; D000293:Adolescent; D000328:Adult; D000368:Aged; D000658:Amoxicillin / Q000009:adverse effects / Q000627:therapeutic use*; D000890:Anti-Infective Agents / Q000009:adverse effects / Q000627:therapeutic use*; D000897:Anti-Ulcer Agents / Q000009:adverse effects / Q000627:therapeutic use*; D001562:Benzimidazoles / Q000009:adverse effects / Q000627:therapeutic use*; D005260:Female; D005500:Follow-Up Studies; D005744:Gastric Acid / Q000378:metabolism; D016481:Helicobacter Infections / Q000188:drug therapy* / Q000382:microbiology; D016480:Helicobacter pylori; D006801:Humans; D064704:Levofloxacin; D008297:Male; D008875:Middle Aged; D015242:Ofloxacin / Q000009:adverse effects / Q000627:therapeutic use*; D009853:Omeprazole / Q000031:analogs & derivatives; D010406:Penicillins / Q000009:adverse effects / Q000627:therapeutic use*; D011446:Prospective Studies; D064750:Rabeprazole; D014011:Tinidazole / Q000009:adverse effects / Q000627:therapeutic use*
chemical_list: D053799:2-Pyridinylmethylsulfinylbenzimidazoles; D000890:Anti-Infective Agents; D000897:Anti-Ulcer Agents; D001562:Benzimidazoles; D010406:Penicillins; D014011:Tinidazole; D064750:Rabeprazole; D064704:Levofloxacin; D000658:Amoxicillin; D015242:Ofloxacin; D009853:Omeprazole